We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+12.02%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.02B
AUM Growth
+$115M
Cap. Flow
+$23.9M
Cap. Flow %
2.35%
Top 10 Hldgs %
71.39%
Holding
43
New
3
Increased
7
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$93.8M
2
ILMN icon
Illumina
ILMN
+$34.2M
3
BLFS icon
BioLife Solutions
BLFS
+$11.8M
4
NTLA icon
Intellia Therapeutics
NTLA
+$7.82M
5
NGNE icon
Neurogene
NGNE
+$7.51M

Top Sells

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$87.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$9.53M
4
MXCT icon
MaxCyte
MXCT
+$5.9M
5
BPMC
Blueprint Medicines
BPMC
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$38.8B
$164M 16.09%
5,714,775
+3,904,775
+216% +$93.8M
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$141M 13.89%
8,707,165
+927,165
+12% +$11.8M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.63B
$97.1M 9.53%
1,006,500
-3,830
-0.4% -$367K
RLAY icon
4
Relay Therapeutics
RLAY
$4.04B
$81.3M 7.98%
7,387,943
+464,369
+7% +$3.92M
GPCR icon
5
Structure Therapeutics
GPCR
$3.39B
$44.5M 4.37%
1,091,867
-166,299
-13% -$9.53M
NTLA icon
6
Intellia Therapeutics
NTLA
$1.5B
$44.2M 4.34%
1,450,000
+271,925
+23% +$7.82M
ILMN icon
7
Illumina
ILMN
$30.2B
$43.6M 4.28%
321,764
+296,064
+1,152% +$34.2M
VERV
8
DELISTED
Verve Therapeutics
VERV
$41.9M 4.12%
3,009,094
+54,384
+2% +$674K
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$29.1B
$37.3M 3.66%
195,000
-5,000
-3% -$852K
SLGC
10
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$31.9M 3.13%
12,604,275
– –
EXAS
11
DELISTED
Exact Sciences
EXAS
$31.1M 3.05%
420,000
-39,450
-9% -$2.59M
BPMC
12
DELISTED
Blueprint Medicines
BPMC
$30.1M 2.96%
326,378
-45,000
-12% -$2.92M
PLRX icon
13
Pliant Therapeutics
PLRX
$64.4M
$28.6M 2.8%
1,577,108
– –
DNLI icon
14
Denali Therapeutics
DNLI
$3.67B
$27.9M 2.74%
1,300,000
– –
FDMT icon
15
4D Molecular Therapeutics
FDMT
$524M
$20.9M 2.06%
1,033,811
– –
TNYA icon
16
Tenaya Therapeutics
TNYA
$161M
$20.7M 2.03%
6,381,377
– –
BEAM icon
17
Beam Therapeutics
BEAM
$2.66B
$14.4M 1.41%
528,000
-42,000
-7% -$1.04M
ABCL icon
18
AbCellera Biologics
ABCL
$1.78B
$13.5M 1.32%
2,360,129
– –
TNGX icon
19
Tango Therapeutics
TNGX
$4.43B
$11.8M 1.15%
1,188,349
-119,000
-9% -$1.03M
IPSC icon
20
Century Therapeutics
IPSC
$353M
$10.6M 1.04%
3,206,380
– –
RNAM
21
DELISTED
Avidity Biosciences
RNAM
$10.6M 1.04%
1,175,750
-74,250
-6% -$496K
NGNE icon
22
Neurogene
NGNE
$657M
$10.2M 1%
+524,616
New +$7.51M
PACB icon
23
Pacific Biosciences
PACB
$441M
$10.2M 1%
1,035,859
– –
WGS icon
24
GeneDx Holdings
WGS
$1.98B
$8.51M 0.84%
3,095,511
– –
FATE icon
25
Fate Therapeutics
FATE
$294M
$7.67M 0.75%
2,050,000
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Casdin Capital held 43 positions worth $1.02B, up 13% from $904M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Casdin Capital's Q4 2023 filing shows 3 new, 7 increased, 9 reduced and 5 closed positions. Its largest new stake was Neurogene: 524,616 shares worth $10.2M. The largest sale was EQRx, Inc. Common Stock, an estimated $87.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Casdin Capital's largest Q4 2023 buy was Neurogene: 524,616 shares worth $10.2M.
  • Casdin Capital added most to Revolution Medicines in Q4 2023, an estimated $93.8M increase.
  • Casdin Capital's biggest Q4 2023 reduction was Structure Therapeutics, cutting an estimated $9.53M.
  • Casdin Capital fully exited EQRx, Inc. Common Stock in Q4 2023, selling an estimated $87.8M.
  • Casdin Capital's ten largest holdings make up 71% of its $1.02B portfolio in Q4 2023.
  • Casdin Capital opened 3 new positions and closed 5 in Q4 2023.
  • Casdin Capital's portfolio value rose 13% quarter-over-quarter to $1.02B.

Based on Casdin Capital's 13F filing for Q4 2023, filed 14 Feb 2024.